PRIMUS 001: A Study Looking at Two Different Chemotherapy Regimens in Patients With Metastatic Pancreatic Cancer
Status:
Recruiting
Trial end date:
2023-11-01
Target enrollment:
Participant gender:
Summary
This study is comparing two combinations of chemotherapy treatments in patients with
metastatic pancreatic cancer. Half the participants will receive FOLFOX-A and the other half
will receive AG. Treatment will continue until progression or patient/clinican decision or
intolerable toxicity.
Phase:
Phase 2
Details
Lead Sponsor:
Judith Dixon-Hughes
Collaborators:
NHS Greater Glasgow and Clyde University of Glasgow